Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.3% – What’s Next?

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) traded down 5.3% on Friday . The stock traded as low as $13.55 and last traded at $13.58. 563,568 shares changed hands during trading, a decline of 52% from the average session volume of 1,179,321 shares. The stock had previously closed at $14.34.

Analyst Ratings Changes

A number of brokerages recently weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group raised their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Piper Sandler began coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald raised their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Down 5.8 %

The company has a fifty day moving average of $18.59 and a 200 day moving average of $9.96.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics in the 3rd quarter worth $133,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at $161,000. Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth about $192,000. BNP Paribas Financial Markets raised its holdings in Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares during the period. Finally, FMR LLC purchased a new stake in Capricor Therapeutics during the third quarter valued at about $370,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.